Precision Imaging Technology to Support Earlier Cancer Detection

Cancer remains a significant health challenge in Indonesia, alongside the increasing need for early detection and personalised treatment approaches. According to 2022 Globocan data (International Agency for Research on Cancer/WHO), there were 408,661 new cancer cases and 242,988 cancer-related deaths recorded in Indonesia. Breast, lung, colorectal, cervical, and liver cancers are the most common types found.

Furthermore, many new patients are diagnosed at advanced stages, reflecting ongoing challenges in early detection and access to comprehensive cancer services. This situation underscores the importance of strengthening oncology service capabilities across Indonesia.

To address these needs, Siemens Healthineers launched the Symbia Pro.Specta at The 6th Siloam Oncology Summit 2026, a precision imaging technology designed to support earlier detection and more personalised cancer management in Indonesia.

“The launch of Symbia Pro.Specta is a significant step in driving the development of precision medicine in Indonesia,” said Alfred Fahringer, President Director of Siemens Healthineers Indonesia, during the summit in Jakarta. He expressed that Siemens Healthineers believes every patient has unique characteristics, meaning their treatment journey should reflect their individual needs.